<ul>
<li>开始将处方药分发优化人工智能平台 EinsteinRx™ 集成到药房客户的销售点系统中</li>
<li>EinsteinRx 集成的简化工作重点是减少入驻过程中的摩擦，并加快实施时间，以便在扩大药房营销工作之前进行</li>
<li>公司预计到 2026 年底，每月将有多达 500 家药房正式加入 Wellgistics 药房网络</li>
<li>制造商供应商关系扩展工作专注于糖尿病、减肥、心脏代谢及长期新冠患者，这些患者是现有药房客户已经服务的对象</li>
<li>PharmacyChain™ 区块链支持的医疗智能合约开发资源评估正在进行中</li>
</ul>
<p><strong>Wellgistics Health, Inc.（&#34;Wellgistics&#34;）（NASDAQ:WGRX）</strong>，一家健康信息技术领导者，将其专有的药房分发优化人工智能（'AI'）平台 <strong>EinsteinRx</strong> <em><strong>™</strong></em> 集成到其专利的区块链支持智能合约平台 <strong>PharmacyChain™</strong> 中，今天向利益相关者提供了 2026 年的公司展望。</p>
<p>&#34;在我重新担任 Wellgistics 总裁的三个月后，公司现在有了明确的方向，我们开始了一个高度专注的运营执行阶段，&#34; Wellgistics Health 的总裁兼临时首席执行官 Prashant Patel, RPh 说道。&#34;到 2026 年，我们将专注于将我们的 EinsteinRx™ AI 平台实施到药房客户的销售点系统中，入驻并增加我们现有的 6500 多家独立药房客户转变为我们官方的 Wellgistics 药房网络（'Wellgistics 药房网络'）的比例。加入 Wellgistics 药房网络的药房的主要好处将是整合从授权提供者数据库中提取的患者特定健康信息与 “及时” 的处方优化工具，以使我们网络的药剂师能够教育提供者和患者选择最佳的个性化处方药及与最佳患者结果相关的处方药附加产品和服务。我们已经开始与我们最亲近的药房客户进行 Wellgistics 药房网络的集成过程，并正在优化入驻流程，以使药剂师的体验尽可能无缝，利用客户反馈来提高部署速度并减少流程摩擦。一旦优化到位，我们打算加速药房转化的营销工作，同时也希望扩大我们的处方药制造商供应商关系。我们的目标是在 2026 年底之前实现每月最多 500 家药房的 Wellgistics 药房网络入驻率。&#34;</p>
<p>帕特尔先生继续说道，&#34;虽然我们专注于优化 EinsteinRx 的首个产品是针对糖尿病市场的 SGLT-2 药物 Brenzavvy®，但我们打算迅速扩大我们的品牌制造商关系，以包括其他主要针对类似患者群体的产品，这些患者群体占 Wellgistics 药房网络药房服务的患者的相当大比例，包括被开处方 GLP-1 激动剂药物和其他与心脏代谢疾病相关的药物的患者，例如长期新冠。&#34;</p>
<p>根据 iData Research，美国糖尿病市场预计在 2024 年为 480 亿美元，到 2031 年将增长至 790 亿美元。根据 Grandview Research，北美 GLP-1 激动剂市场预计在 2025 年为 530 亿美元，到 2030 年将增长至 1560 亿美元。根据 Mobility Forsights，美国心脏代谢疾病市场预计在 2024 年为 460 亿美元，到 2031 年将增长至 850 亿美元。根据 Nature Publication Journals Primary Care Respiratory Medicine 发布的研究，美国超过 1800 万患者每年平均损失超过 9000 美元，总损失工资估计超过 1700 亿美元。</p>
<p>&#34;与这一入驻优化工作同时，我们的技术团队一直在评估建立 PharmacyChain 所需的资源，&#34;帕特尔先生补充道。&#34;我们很快将提供有关这一令人兴奋的工作的更新，我们预计这将显著提高医疗服务市场的效率。PharmacyChain 正在开发中，以实施端到端的智能合约，以大幅减少与最佳医疗服务相关的行政负担，提高支付方透明度，并显著增加美国药房、提供者和其他利益相关者的及时保险报销率，同时根除医疗系统中的欺诈、浪费和滥用。&#34;</p>
<p><strong>关于 Wellgistics Health, Inc.</strong></p>
<p>Wellgistics Health（NASDAQ: WGRX）是一家健康信息技术领导者，将其专有的药房分发优化人工智能平台 EinsteinRx™ 集成到其专利的区块链支持智能合约平台 PharmacyChain™ 中，以优化处方药分发过程。其集成平台连接了 6500 多家药房（&#34;Wellgistics 药房网络&#34;）和 200 多家制造商，提供批发分销、数字处方路由、直接送药到患者以及基于 AI 的中心服务，如资格审核、依从性、入驻、事先授权和现金支付履行，以优化患者的获取。Wellgistics 提供端到端解决方案，旨在恢复美国独立药房处方药市场的获取、透明度和信任。</p>
<p>欲了解更多信息，请访问 www.wellgisticshealth.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据联邦证券法定义的前瞻性声明，包括但不限于关于各方计划谈判最终协议、潜在实施、采用、绩效、收入分享及其他预期的合作利益的声明。这些声明受到风险和不确定性的影响，可能导致实际结果与预期有重大差异，包括在 DataVault AI, Inc.和 Wellgistics Health, Inc.向 SEC 提交的文件中所描述的风险。前瞻性声明仅在本日期有效，且两家公司均不承担除法律要求外的任何更新义务。其他因素在 Wellgistics Health 向 SEC 提交的文件中进行了讨论，详见 www.sec.gov。</p>
<p>本新闻稿不构成在任何司法管辖区内出售或招揽购买任何证券的要约，并且在任何此类要约、招揽或销售违法的司法管辖区内均不应出售证券。</p>
<p><strong>Wellgistics 媒体与投资者联系</strong></p>
<p>媒体：</p>
<p>media@wellgisticshealth.com</p>
<p>投资者关系：</p>
<p>IR@wellgisticshealth.com</p>
<p><strong>来源：</strong> Wellgistics Health, Inc.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNDg3Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNDg3Mw"/></p>

WGRX

<p>Wellgistics Health, Inc.（纳斯达克代码：WGRX）已概述其 2026 年的企业展望，重点是将其人工智能平台 EinsteinRx™整合到药房销售点系统中。该公司计划到 2026 年底每月新增多达 500 家药房加入其 Wellgistics 药房网络。此外，Wellgistics 还计划扩大与针对糖尿病和心脏代谢患者的药品制造商的关系。其区块链支持的智能合约平台 PharmacyChain™的开发也在进行中，以提高医疗服务的效率和透明度</p>

<ul>
<li>Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced</li>
<li>EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort</li>
<li>Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026</li>
<li>Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic &amp; Long COVID patients that existing pharmacy clients already serve</li>
<li>PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing</li>
</ul>
<div class="lb-trans"><ul>
<li>开始将处方药分发优化人工智能平台 EinsteinRx™ 集成到药房客户的销售点系统中</li>
<li>EinsteinRx 集成的简化工作重点是减少入驻过程中的摩擦，并加快实施时间，以便在扩大药房营销工作之前进行</li>
<li>公司预计到 2026 年底，每月将有多达 500 家药房正式加入 Wellgistics 药房网络</li>
<li>制造商供应商关系扩展工作专注于糖尿病、减肥、心脏代谢及长期新冠患者，这些患者是现有药房客户已经服务的对象</li>
<li>PharmacyChain™ 区块链支持的医疗智能合约开发资源评估正在进行中</li>
</ul>
</div><p><strong>Wellgistics Health, Inc. (&#34;Wellgistics&#34;) (NASDAQ:WGRX)</strong>, a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence ('AI') platform <strong>EinsteinRx</strong> <em><strong>™</strong></em> into its patented blockchain-enabled smart contracts platform <strong>PharmacyChain™</strong>, today provided a corporate outlook for 2026 to stakeholders.</p>
<div class="lb-trans"><p><strong>Wellgistics Health, Inc.（&#34;Wellgistics&#34;）（NASDAQ:WGRX）</strong>，一家健康信息技术领导者，将其专有的药房分发优化人工智能（'AI'）平台 <strong>EinsteinRx</strong> <em><strong>™</strong></em> 集成到其专利的区块链支持智能合约平台 <strong>PharmacyChain™</strong> 中，今天向利益相关者提供了 2026 年的公司展望。</p>
</div><p>&#34;Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase,&#34; said Prashant Patel, RPh, President &amp; Interim-CEO of Wellgistics Health. &#34;In 2026 we will focus squarely on the implementation of our EinsteinRx™ AI platform into pharmacy client point of sale systems, onboarding and increasing the percentage of our existing 6,500+ independent pharmacy customers that convert into our official Wellgistics pharmacy network (the 'Wellgistics Pharmacy Network'). The key benefit for pharmacies enrolling in the Wellgistics Pharmacy Network will be the integration of patient-specific health information pulled from authorized provider databases with 'just-in-time' prescription optimization tools to empower our network's pharmacists to educate both providers and patients on the best personalized prescription drug selection and prescription drug-adjacent products &amp; services that are associated with the best patient outcomes. We have already started the Wellgistics Pharmacy Network integration process with our closest pharmacy customers and are currently optimizing the onboarding process to make it as seamless as possible for pharmacists, leveraging client feedback to improve speed of deployment and reduce process friction. Once sufficiently optimized, we intend to accelerate the pharmacy conversion marketing effort as we also look to expand our prescription drug manufacturer supplier relationships. We have set a goal of reaching a Wellgistics Pharmacy Network onboarding rate of up to 500 pharmacies per month by year end 2026.&#34;</p>
<div class="lb-trans"><p>&#34;在我重新担任 Wellgistics 总裁的三个月后，公司现在有了明确的方向，我们开始了一个高度专注的运营执行阶段，&#34; Wellgistics Health 的总裁兼临时首席执行官 Prashant Patel, RPh 说道。&#34;到 2026 年，我们将专注于将我们的 EinsteinRx™ AI 平台实施到药房客户的销售点系统中，入驻并增加我们现有的 6500 多家独立药房客户转变为我们官方的 Wellgistics 药房网络（'Wellgistics 药房网络'）的比例。加入 Wellgistics 药房网络的药房的主要好处将是整合从授权提供者数据库中提取的患者特定健康信息与 “及时” 的处方优化工具，以使我们网络的药剂师能够教育提供者和患者选择最佳的个性化处方药及与最佳患者结果相关的处方药附加产品和服务。我们已经开始与我们最亲近的药房客户进行 Wellgistics 药房网络的集成过程，并正在优化入驻流程，以使药剂师的体验尽可能无缝，利用客户反馈来提高部署速度并减少流程摩擦。一旦优化到位，我们打算加速药房转化的营销工作，同时也希望扩大我们的处方药制造商供应商关系。我们的目标是在 2026 年底之前实现每月最多 500 家药房的 Wellgistics 药房网络入驻率。&#34;</p>
</div><p>Mr. Patel continued, &#34;While SGLT-2 drug Brenzavvy® for the diabetes market is the first product that we are focused on optimizing EinsteinRx for, we intend to quickly expand our branded manufacturer relationships to include other products that primarily target similar patient populations that make up a significant proportion of the patients Wellgistics Pharmacy Network pharmacies serve, including patients who have been prescribed GLP-1 agonist drugs and other drugs associated with cardiometabolic disease, such as Long COVID.&#34;</p>
<div class="lb-trans"><p>帕特尔先生继续说道，&#34;虽然我们专注于优化 EinsteinRx 的首个产品是针对糖尿病市场的 SGLT-2 药物 Brenzavvy®，但我们打算迅速扩大我们的品牌制造商关系，以包括其他主要针对类似患者群体的产品，这些患者群体占 Wellgistics 药房网络药房服务的患者的相当大比例，包括被开处方 GLP-1 激动剂药物和其他与心脏代谢疾病相关的药物的患者，例如长期新冠。&#34;</p>
</div><p>The US diabetes market was estimated to be $48 billion in 2024, growing to $79 billions by 2031 according to iData Research. The North American GLP-1 agonist market was estimated to be $53 billion in 2025, respected to grow to $156 billion by 2030 according to Grandview Research. The US cardiometabolic disorders market was estimated to be $46 billion in 2024, expected to grow to $85 billion by 2031 according to Mobility Forsights. Over 18 million patients in the United States lose an annual average of over $9,000 per patient, resulting in total lost wages estimated at over $170 billion annually according to research published in Nature Publication Journals Primary Care Respiratory Medicine.</p>
<div class="lb-trans"><p>根据 iData Research，美国糖尿病市场预计在 2024 年为 480 亿美元，到 2031 年将增长至 790 亿美元。根据 Grandview Research，北美 GLP-1 激动剂市场预计在 2025 年为 530 亿美元，到 2030 年将增长至 1560 亿美元。根据 Mobility Forsights，美国心脏代谢疾病市场预计在 2024 年为 460 亿美元，到 2031 年将增长至 850 亿美元。根据 Nature Publication Journals Primary Care Respiratory Medicine 发布的研究，美国超过 1800 万患者每年平均损失超过 9000 美元，总损失工资估计超过 1700 亿美元。</p>
</div><p>&#34;Concurrent with this onboarding optimization effort, our technology team has been working to complete its assessment of the resources required to establish PharmacyChain,&#34; added Mr. Patel. &#34;We will very soon provide updates on this exciting effort that we expect will dramatically improve efficiency in the healthcare delivery market. PharmacyChain is being developed to implement end-to-end smart contracts to drastically reduce the administrative burden associated with optimal healthcare delivery, improve payer transparency and significantly increase the rate of timely insurance reimbursements for pharmacies, providers and other stakeholders in the United States while simultaneously rooting out fraud, waste and abuse in the healthcare system.&#34;</p>
<div class="lb-trans"><p>&#34;与这一入驻优化工作同时，我们的技术团队一直在评估建立 PharmacyChain 所需的资源，&#34;帕特尔先生补充道。&#34;我们很快将提供有关这一令人兴奋的工作的更新，我们预计这将显著提高医疗服务市场的效率。PharmacyChain 正在开发中，以实施端到端的智能合约，以大幅减少与最佳医疗服务相关的行政负担，提高支付方透明度，并显著增加美国药房、提供者和其他利益相关者的及时保险报销率，同时根除医疗系统中的欺诈、浪费和滥用。&#34;</p>
</div><p><strong>About Wellgistics Health, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Wellgistics Health, Inc.</strong></p>
</div><p>Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the &#34;Wellgistics Pharmacy Network&#34;) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.</p>
<div class="lb-trans"><p>Wellgistics Health（NASDAQ: WGRX）是一家健康信息技术领导者，将其专有的药房分发优化人工智能平台 EinsteinRx™ 集成到其专利的区块链支持智能合约平台 PharmacyChain™ 中，以优化处方药分发过程。其集成平台连接了 6500 多家药房（&#34;Wellgistics 药房网络&#34;）和 200 多家制造商，提供批发分销、数字处方路由、直接送药到患者以及基于 AI 的中心服务，如资格审核、依从性、入驻、事先授权和现金支付履行，以优化患者的获取。Wellgistics 提供端到端解决方案，旨在恢复美国独立药房处方药市场的获取、透明度和信任。</p>
</div><p>For more information, visit www.wellgisticshealth.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.wellgisticshealth.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.</p>
<div class="lb-trans"><p>本新闻稿包含根据联邦证券法定义的前瞻性声明，包括但不限于关于各方计划谈判最终协议、潜在实施、采用、绩效、收入分享及其他预期的合作利益的声明。这些声明受到风险和不确定性的影响，可能导致实际结果与预期有重大差异，包括在 DataVault AI, Inc.和 Wellgistics Health, Inc.向 SEC 提交的文件中所描述的风险。前瞻性声明仅在本日期有效，且两家公司均不承担除法律要求外的任何更新义务。其他因素在 Wellgistics Health 向 SEC 提交的文件中进行了讨论，详见 www.sec.gov。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</p>
<div class="lb-trans"><p>本新闻稿不构成在任何司法管辖区内出售或招揽购买任何证券的要约，并且在任何此类要约、招揽或销售违法的司法管辖区内均不应出售证券。</p>
</div><p><strong>Wellgistics Media &amp; Investor Contact</strong></p>
<div class="lb-trans"><p><strong>Wellgistics 媒体与投资者联系</strong></p>
</div><p>Media:</p>
<div class="lb-trans"><p>媒体：</p>
</div><p>media@wellgisticshealth.com</p>
<div class="lb-trans"><p>media@wellgisticshealth.com</p>
</div><p>Investor Relations:</p>
<div class="lb-trans"><p>投资者关系：</p>
</div><p>IR@wellgisticshealth.com</p>
<div class="lb-trans"><p>IR@wellgisticshealth.com</p>
</div><p><strong>SOURCE:</strong> Wellgistics Health, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Wellgistics Health, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNDg3Mw" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1124873"/></p>

Wellgistics Health 发布 2026 年公司展望 | WGRX 股票新闻